Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma

Phase 2 Unknown 30 enrolled Zhejiang Cancer Hospital

NaSingle-groupOpen-labelTreatment

Summary

The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).

Timeline

Start: 2012-05
Primary completion: 2013-12
Completion: 2014-05

Publications

Jin T, Li B, Chen XZ. A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286). Oncol Res. 2013;21(6):317-23. doi: 10.3727/096504014X13983417587401.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Endostar	Protein / enzyme biologic	15 mg	—
Background	Cisplatin	Other / unclassified	80 mg/m2	—
Background	Gemcitabine	Small molecule	1000 mg/m2	—

Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma

Summary

Timeline

Publications

Drugs

Indications